Patents by Inventor Tahir Nadeem Majid
Tahir Nadeem Majid has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8129537Abstract: This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.Type: GrantFiled: January 26, 2010Date of Patent: March 6, 2012Assignees: Rhone-Poulenc Rorer Limited, Aventis Pharma LimitedInventors: Garry Fenton, Tahir Nadeem Majid, Malcolm Norman Palfreyman
-
Publication number: 20100240677Abstract: This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.Type: ApplicationFiled: January 26, 2010Publication date: September 23, 2010Applicant: AVENTIS PHARMA LIMITEDInventors: Garry FENTON, Tahir Nadeem MAJID, Malcolm Norman PALFREYMAN
-
Patent number: 7652144Abstract: A compound of formula XIX wherein R1, R2, Z1, Z2, Q1, Q2 and Q3 as defined in the specification.Type: GrantFiled: June 18, 2007Date of Patent: January 26, 2010Assignee: Aventis Pharma LimitedInventors: Garry Fenton, Tahir Nadeem Majid, Malcolm Norman Palfreyman
-
Publication number: 20080132706Abstract: This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.Type: ApplicationFiled: June 18, 2007Publication date: June 5, 2008Applicant: AVENTIS PHARMA LIMITEDInventors: Garry FENTON, Tahir Nadeem MAJID, Malcolm Norman PALFREYMAN
-
Patent number: 7259154Abstract: Compounds of the formula and N-oxides, prodrugs, acid bioisosteres, pharmaceutically acceptable salts or solvates of such compounds, or N-oxides, prodrugs, or acid bioisosteres of such salts or solvates, to compositions comprising such compounds, and methods of treatment comprising administering, to a patient in need thereof, such compounds and compositions.Type: GrantFiled: December 23, 2003Date of Patent: August 21, 2007Assignee: Aventis Pharmaceuticals Inc.Inventors: Paul Joseph Cox, Tahir Nadeem Majid, Stephanie Daniele Deprets, Shelley Amendola, Iain McFarlane McLay, Christopher Edlin, David John Aldous, Brian Pedgrift, Frank Halley, Michael Edwards, Bernard Baudoin
-
Patent number: 7227020Abstract: Chemical compositions containing physiologically active compounds of general formula (I): wherein R1 is aryl or heteroaryl; R2 represents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocycloalkyl, -Z1R8, —C(?O)—NY3Y4, —CO2R8, —NY3Y4, —N(R6)—C(?O)—R7, —N(R6)—C(?O)—NY3Y4, —N(R6)—C(?O)—OR7, —N(R6)—SO2—R7, —N(R6)—SO2—NY3Y4 and one or more halogen atoms; R3 represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, —C(?O)—OR5 or —C(?O)—NY3Y; and X1 represents N, CH, C-halo, C—CN, C—R7, C—NY3Y4, C—OH, C-Z2R7, C—C(?O)—OR5, C—C(?O)—NY3Y4, C—N(R8)—C(?O)—R7, C—SO2—NY3Y4, C—N(R8)—SO2—R7, C-alkenyl, C-alkynyl or C—NO2; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit protein kinases.Type: GrantFiled: April 20, 2004Date of Patent: June 5, 2007Assignee: Aventis Pharma LimitedInventors: Paul Joseph Cox, Tahir Nadeem Majid, Shelley Amendola, Stephanie Daniele Deprets, Christoper David Edlin, Justine Yeun Quai Lai, Andrew David Morley
-
Patent number: 7148215Abstract: The present invention concerns compounds of general formula (I): in which the substituents are as described herein.Type: GrantFiled: March 18, 2004Date of Patent: December 12, 2006Assignee: Aventis Pharma S.A.Inventors: Andrew James Ratcliffe, Roger John Aitchison Walsh, Tahir Nadeem Majid, Sukanthini Thurairatnam, Shelley Amendola, David John Aldous, John Edward Souness, Conception Nemecek, Sylvie Wentzler, Corinne Venot
-
Patent number: 7132428Abstract: Compounds of the formula I are suitable for producing pharmaceuticals for the prophylaxis and therapy of diseases whose course involves an increased activity of NIK.Type: GrantFiled: July 3, 2003Date of Patent: November 7, 2006Assignee: Aventis Pharmaceuticals Inc.Inventors: Tahir Nadeem Majid, Corey Hopkins, Brian Leslie Pedgrift, Nicola Collar, Friederike Wirtz-Brugger, Jean Merrill
-
Patent number: 7045660Abstract: This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.Type: GrantFiled: March 3, 2004Date of Patent: May 16, 2006Assignee: Aventis Pharma LimitedInventors: Garry Fenton, Tahir Nadeem Majid, Malcolm Norman Palfreyman
-
Publication number: 20040171618Abstract: This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF).Type: ApplicationFiled: March 3, 2004Publication date: September 2, 2004Applicant: AVENTIS PHARMA LIMITEDInventors: Garry Fenton, Tahir Nadeem Majid, Malcolm Norman Palfreyman
-
Publication number: 20040142947Abstract: Compounds of the formula 1Type: ApplicationFiled: December 23, 2003Publication date: July 22, 2004Applicant: Aventis Pharmaceuticals, Inc.Inventors: Paul Joseph Cox, Tahir Nadeem Majid, Stephanie Daniele Deprets, Shelley Amendola, Iain McFarlane McLay, Christopher Edlin, David John Aldous, Brian Pedgrift, Frank Halley, Michael Edwards, Bernard Baudoin
-
Patent number: 6472412Abstract: This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.Type: GrantFiled: January 26, 1996Date of Patent: October 29, 2002Assignee: Aventis Pharma LimitedInventors: Garry Fenton, Tahir Nadeem Majid, Malcolm Norman Palfreyman